表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR-TKI)获得性耐药和原发性耐药至今仍是临床治疗晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)的瓶颈。STE029是一种同时具有羟甲基戊二酸单酰辅酶A还原酶(3-hydroxy-3-methylglutarylcoenzyme A reductase, HMGCR)抑制剂抗肿瘤作用和肿瘤特异性细胞膜靶向功能的新型抗肿瘤药物。本研究旨在探讨STE029逆转肺腺癌EGFR-TKI的耐药机制。. The gene discussed is HMGCR; the disease is non-small cell lung carcinoma.